Figure 3From: Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial Mean (95% CI) change from baseline to endpoint in CAARS:O-SV score. Subjects defined as adherent (> 95% overall adherence) or non-adherent in the (a) main analysis set; and (b) completer population.Back to article page